Eris Lifesciences Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Amit Bakshi

Geschäftsführender

₹48.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts35.9%
Amtszeit als Geschäftsführer17.7yrs
Eigentum des Geschäftsführers42.9%
Durchschnittliche Amtszeit des Managements8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.9yrs

Jüngste Management Updates

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Recent updates

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28
Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

Sep 23
Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

May 26
If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 17
Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Mar 12
Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Feb 25
Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Feb 12
Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Jan 30
Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Jan 17
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Dec 30
Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 10
Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?

Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year

Nov 23
Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year

Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?

Oct 22
Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Amit Bakshi im Vergleich zu den Einnahmen von Eris Lifesciences verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

₹4b

Mar 31 2024₹49m₹17m

₹4b

Dec 31 2023n/an/a

₹4b

Sep 30 2023n/an/a

₹4b

Jun 30 2023n/an/a

₹4b

Mar 31 2023₹49m₹17m

₹4b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹46m₹26m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹4b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹27m₹27m

₹4b

Dec 31 2020n/an/a

₹3b

Sep 30 2020n/an/a

₹3b

Jun 30 2020n/an/a

₹3b

Mar 31 2020₹49m₹18m

₹3b

Dec 31 2019n/an/a

₹3b

Sep 30 2019n/an/a

₹3b

Jun 30 2019n/an/a

₹3b

Mar 31 2019₹49m₹18m

₹3b

Dec 31 2018n/an/a

₹3b

Sep 30 2018n/an/a

₹3b

Jun 30 2018n/an/a

₹3b

Mar 31 2018₹49m₹11m

₹3b

Vergütung im Vergleich zum Markt: AmitDie Gesamtvergütung ($USD581.61K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Indian ($USD473.89K).

Entschädigung vs. Einkommen: AmitDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

Amit Bakshi (49 yo)

17.7yrs

Amtszeit

₹48,776,648

Vergütung

Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Amit Bakshi
Chairman & MDno data₹48.78m42.87%
₹ 74.4b
Sachin Shah
Chief Financial Officer8yrs₹18.01mkeine Daten
Krishnakumar Vaidyanathan
Executive Director & COO3.3yrs₹44.85mkeine Daten
Gagan Atreja
President of Sales & Marketingno data₹22.05mkeine Daten
Inderjeet Negi
Executive Directorno data₹12.40m4.36%
₹ 7.6b
Kaushal Shah
Whole Time Directorno data₹6.99m3.28%
₹ 5.7b
Deepak Kapoor
Senior Vice Presidentno data₹13.72mkeine Daten
Milind Talegaonkar
Compliance Officer & Company Secretary8yrskeine Datenkeine Daten
Vijay Joshi
President Medicalno data₹12.31mkeine Daten
Manish Kapoor
Vice Presidentno data₹12.36mkeine Daten
Alok Mahajan
Vice Presidentno data₹13.30mkeine Daten
Viraj Suvarna
Vice Presidentno data₹15.08mkeine Daten

8.0yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von ERIS ist erfahren und erfahren (durchschnittliche Amtszeit: 7.7 Jahre).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Amit Bakshi
Chairman & MD17.7yrs₹48.78m42.87%
₹ 74.4b
Krishnakumar Vaidyanathan
Executive Director & COO3.8yrs₹44.85mkeine Daten
Inderjeet Negi
Executive Director17.7yrs₹12.40m4.36%
₹ 7.6b
Kaushal Shah
Whole Time Director4.1yrs₹6.99m3.28%
₹ 5.7b
Prashant Gupta
Independent Non-Executive Director6.4yrs₹4.13mkeine Daten
Sujesh Vasudevan
Independent Non-Executive Director2.2yrs₹4.05mkeine Daten
Kalpana Unadkat
Independent Non-Executive Director3.7yrs₹4.51mkeine Daten
Rajeev Dalal
Independent Non-Executive Director3.8yrs₹4.65mkeine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrener Vorstand: ERISDie Vorstandsmitglieder gelten als erfahren (3.6 Jahre durchschnittliche Amtszeit).